Forskning ved Københavns Universitet - Københavns Universitet

Forside

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. / Balestri, Francesca; Santini, Simone.

I: Therapeutics and Clinical Risk Management, Bind 3, Nr. 2, 2007, s. 269-75.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Balestri, F & Santini, S 2007, 'Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.', Therapeutics and Clinical Risk Management, bind 3, nr. 2, s. 269-75.

APA

Balestri, F., & Santini, S. (2007). Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. Therapeutics and Clinical Risk Management, 3(2), 269-75.

Vancouver

Balestri F, Santini S. Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. Therapeutics and Clinical Risk Management. 2007;3(2):269-75.

Author

Balestri, Francesca ; Santini, Simone. / Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. I: Therapeutics and Clinical Risk Management. 2007 ; Bind 3, Nr. 2. s. 269-75.

Bibtex

@article{11bb56c0acae11ddb5e9000ea68e967b,
title = "Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.",
abstract = "Anemia is a common, but underestimated and undertreated, complication of patients with cancer receiving chemo- or radiotherapy, and negatively affects their quality of life (QoL). Erythropoietic proteins (EPS) offer an effective treatment of cancer anemia and ameliorate QoL, although their use requires the correct targeting of hemoglobin increase to avoid thromboembolic complications. Currently the effort is focused on offering patients this effective treatment with reduced frequency of administration. Higher weekly single doses of recombinant human Epo (rHuEpo) either alpha or beta, instead of three times per week, have been proposed for the treatment. The pharmacokinetic and pharmacodynamic characteristics of the hyperglycosylated protein darbepoetin alpha permit even longer inter vals between administrations. Every other week or every three weeks schedules have shown results (erythropoietic response, reduction of transfusion requirements, and improvement of QoL) comparable with those of weekly rHuEpo.",
author = "Francesca Balestri and Simone Santini",
year = "2007",
language = "English",
volume = "3",
pages = "269--75",
journal = "Therapeutics and Clinical Risk Management (Print)",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

AU - Balestri, Francesca

AU - Santini, Simone

PY - 2007

Y1 - 2007

N2 - Anemia is a common, but underestimated and undertreated, complication of patients with cancer receiving chemo- or radiotherapy, and negatively affects their quality of life (QoL). Erythropoietic proteins (EPS) offer an effective treatment of cancer anemia and ameliorate QoL, although their use requires the correct targeting of hemoglobin increase to avoid thromboembolic complications. Currently the effort is focused on offering patients this effective treatment with reduced frequency of administration. Higher weekly single doses of recombinant human Epo (rHuEpo) either alpha or beta, instead of three times per week, have been proposed for the treatment. The pharmacokinetic and pharmacodynamic characteristics of the hyperglycosylated protein darbepoetin alpha permit even longer inter vals between administrations. Every other week or every three weeks schedules have shown results (erythropoietic response, reduction of transfusion requirements, and improvement of QoL) comparable with those of weekly rHuEpo.

AB - Anemia is a common, but underestimated and undertreated, complication of patients with cancer receiving chemo- or radiotherapy, and negatively affects their quality of life (QoL). Erythropoietic proteins (EPS) offer an effective treatment of cancer anemia and ameliorate QoL, although their use requires the correct targeting of hemoglobin increase to avoid thromboembolic complications. Currently the effort is focused on offering patients this effective treatment with reduced frequency of administration. Higher weekly single doses of recombinant human Epo (rHuEpo) either alpha or beta, instead of three times per week, have been proposed for the treatment. The pharmacokinetic and pharmacodynamic characteristics of the hyperglycosylated protein darbepoetin alpha permit even longer inter vals between administrations. Every other week or every three weeks schedules have shown results (erythropoietic response, reduction of transfusion requirements, and improvement of QoL) comparable with those of weekly rHuEpo.

M3 - Journal article

C2 - 18360635

VL - 3

SP - 269

EP - 275

JO - Therapeutics and Clinical Risk Management (Print)

JF - Therapeutics and Clinical Risk Management (Print)

SN - 1176-6336

IS - 2

ER -

ID: 8463228